Insider Buying at Prenetics Global, Venu Holding, and CTT Pharmaceutical
Sourced from public SEC EDGAR filings. Informational only — not investment advice, and not a recommendation to buy, sell, or hold any security.
Three Form 4 filings hit SEC EDGAR covering open-market purchases by company insiders. Below is what each filing reports: who bought, how many shares, at what price, and on what date.
Prenetics Global Ltd (PRE)
Danny Sheng Wu Yeung, who is listed on the filing as both a director and Chief Executive Officer of Prenetics Global Ltd, reported three separate purchases:
| Date | Shares | Price per Share | Approx. Value |
|---|---|---|---|
| 2026-08-20 | 7,500 | $18.31 | $137,325.00 |
| 2026-08-24 | 6,000 | $20.90 | $125,400.00 |
| 2026-08-24 | 11,181 | $21.40 | $239,273.40 |
Across the three trades, Yeung purchased a combined 24,681 shares for a total of roughly $501,998.40. The filing marks Yeung as a director and officer but not a greater-than-10% beneficial owner.
Filing details: SEC EDGAR index, accession 0001628280-26-058760.
Venu Holding Corp (VENU)
Jay W. Roth, identified in the filing as CEO & Chairman, reported a purchase of 1,000 shares at $1.9176 per share on 2026-08-21, worth approximately $1,917.60.
| Date | Shares | Price per Share | Approx. Value |
|---|---|---|---|
| 2026-08-21 | 1,000 | $1.9176 | $1,917.60 |
Roth is marked in the filing as a director, an officer, and a greater-than-10% beneficial owner, meaning all three Section 16 reporting categories apply to the same individual.
Filing details: SEC EDGAR index, accession 0001493152-26-039935.
CTT Pharmaceutical Holdings, Inc. (CTTH)
A Form 4 for CTT Pharmaceutical Holdings, Inc. (ticker CTTH) reports a purchase of 2,100 shares at $0.055 per share on 2026-08-24, worth approximately $115.50.
| Date | Shares | Price per Share | Approx. Value |
|---|---|---|---|
| 2026-08-24 | 2,100 | $0.055 | $115.50 |
The reporting owner on this filing is listed as “CTT Pharmaceutical Holdings, Inc.” itself, with the officer title given as CEO. The filing marks this reporting person as an officer but not a director and not a greater-than-10% owner. As filed, the owner field and issuer name are identical.
Filing details: SEC EDGAR index, accession 0001035422-26-000007.
Filer Roles at a Glance
All three filings mark the reporting person as an officer. Yeung (Prenetics) and Roth (Venu) are also marked as directors. Roth is additionally marked as a greater-than-10% beneficial owner. Yeung and the CTT Pharmaceutical Holdings filer are not marked as greater-than-10% owners, and the CTT filing does not mark its reporting person as a director.
Sourced directly from Form 4 filings on SEC EDGAR. Not investment advice; see About for what this site does and doesn’t do.